A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
Ontology highlight
ABSTRACT: This expanded access study will assess the efficacy and safety of intravenous (IV) bevacizumab in combination with chemotherapy regimens as first-line treatment of metastatic cancer of the colon or rectum. The anticipated median time on study treatment is approximately 10 months, and the target sample size is 40 individuals.
DISEASE(S): Neoplasm Metastasis,Colorectal Cancer,Colonic Neoplasms
PROVIDER: 2200653 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA